Cargando…
Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model
Aluminum is the most abundant metal that can get admission to the human through several means that include our food, drinking water, cans, drugs, and deodorants, causing neurodegenerative diseases such as Alzheimer’s disease (AD). The present study aims to evaluate the role of quercetin nanoemulsion...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598210/ https://www.ncbi.nlm.nih.gov/pubmed/36290710 http://dx.doi.org/10.3390/antiox11101986 |
_version_ | 1784816276148846592 |
---|---|
author | Alaqeel, Nouf K. AlSheikh, Mona H. Al-Hariri, Mohammed T. |
author_facet | Alaqeel, Nouf K. AlSheikh, Mona H. Al-Hariri, Mohammed T. |
author_sort | Alaqeel, Nouf K. |
collection | PubMed |
description | Aluminum is the most abundant metal that can get admission to the human through several means that include our food, drinking water, cans, drugs, and deodorants, causing neurodegenerative diseases such as Alzheimer’s disease (AD). The present study aims to evaluate the role of quercetin nanoemulsion (QCNE) in attenuating neuronal dysfunction in aluminum chloride (AlCl(3))-induced experimental AD. All animals were classified into six groups including negative control group (I): received a vehicle; QC group: received intraperitoneal (IP) injection of QC; Alzheimer’s group: received AlCl(3) orally; treated group (I): received AlCl(3) orally and IP injection of QC; treated group (II): received AlCl(3) orally and QC orally; and treated group (III): received AlCl(3) orally and IP injection of QCNE. At the end of the experimental period (30 days), the brain was used to study biochemical parameters (measurement of neurotransmitters (serotonin, dopamine, and norepinephrine), oxidant/antioxidant parameters (reduced glutathione, malondialdehyde, superoxide dismutase, and advanced oxidation protein product), and inflammatory markers (adiponectin, interleukin 1β, and plasma tumor necrosis factor-alpha)), while another part was for brain immune-histochemical analysis (study cyclooxygenases (COX-1 and COX-2)). Results showed that the mean value of oxidative stress markers was significantly increased in the AD group as well as the inflammatory biomarkers and all the study neurotransmitters, whereas these parameters were attenuated in treated groups, especially those that received QCNE. The immunohistochemistry findings confirm our results. Both approaches (QC and QCNE) succeeded in retracting the negative impact of AlCl(3). Meanwhile, the effect of QCNE is more potent in mitigating the impact mediated by AlCl(3) in treated animals. In conclusion, the treatment mainly by QCNE has huge potential in protecting against AlCl3-induced neuronal dysfunction, as shown in our results by the elevation of brain antioxidant/anti-inflammatory activities and neurotransmitter levels as well as mending of the histopathological changes in animal models. |
format | Online Article Text |
id | pubmed-9598210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95982102022-10-27 Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model Alaqeel, Nouf K. AlSheikh, Mona H. Al-Hariri, Mohammed T. Antioxidants (Basel) Article Aluminum is the most abundant metal that can get admission to the human through several means that include our food, drinking water, cans, drugs, and deodorants, causing neurodegenerative diseases such as Alzheimer’s disease (AD). The present study aims to evaluate the role of quercetin nanoemulsion (QCNE) in attenuating neuronal dysfunction in aluminum chloride (AlCl(3))-induced experimental AD. All animals were classified into six groups including negative control group (I): received a vehicle; QC group: received intraperitoneal (IP) injection of QC; Alzheimer’s group: received AlCl(3) orally; treated group (I): received AlCl(3) orally and IP injection of QC; treated group (II): received AlCl(3) orally and QC orally; and treated group (III): received AlCl(3) orally and IP injection of QCNE. At the end of the experimental period (30 days), the brain was used to study biochemical parameters (measurement of neurotransmitters (serotonin, dopamine, and norepinephrine), oxidant/antioxidant parameters (reduced glutathione, malondialdehyde, superoxide dismutase, and advanced oxidation protein product), and inflammatory markers (adiponectin, interleukin 1β, and plasma tumor necrosis factor-alpha)), while another part was for brain immune-histochemical analysis (study cyclooxygenases (COX-1 and COX-2)). Results showed that the mean value of oxidative stress markers was significantly increased in the AD group as well as the inflammatory biomarkers and all the study neurotransmitters, whereas these parameters were attenuated in treated groups, especially those that received QCNE. The immunohistochemistry findings confirm our results. Both approaches (QC and QCNE) succeeded in retracting the negative impact of AlCl(3). Meanwhile, the effect of QCNE is more potent in mitigating the impact mediated by AlCl(3) in treated animals. In conclusion, the treatment mainly by QCNE has huge potential in protecting against AlCl3-induced neuronal dysfunction, as shown in our results by the elevation of brain antioxidant/anti-inflammatory activities and neurotransmitter levels as well as mending of the histopathological changes in animal models. MDPI 2022-10-05 /pmc/articles/PMC9598210/ /pubmed/36290710 http://dx.doi.org/10.3390/antiox11101986 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alaqeel, Nouf K. AlSheikh, Mona H. Al-Hariri, Mohammed T. Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title | Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title_full | Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title_fullStr | Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title_full_unstemmed | Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title_short | Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model |
title_sort | quercetin nanoemulsion ameliorates neuronal dysfunction in experimental alzheimer’s disease model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598210/ https://www.ncbi.nlm.nih.gov/pubmed/36290710 http://dx.doi.org/10.3390/antiox11101986 |
work_keys_str_mv | AT alaqeelnoufk quercetinnanoemulsionamelioratesneuronaldysfunctioninexperimentalalzheimersdiseasemodel AT alsheikhmonah quercetinnanoemulsionamelioratesneuronaldysfunctioninexperimentalalzheimersdiseasemodel AT alharirimohammedt quercetinnanoemulsionamelioratesneuronaldysfunctioninexperimentalalzheimersdiseasemodel |